Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evofosfamide (TH-302) in Relapsed/Refractory Multiple Myeloma
NCT01522872Phase 2Unknown
- Sponsor
- Threshold Pharmaceuticals
- Start
- Feb 2012
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of evofosfamide in multiple myeloma (MM), sponsored by Threshold Pharmaceuticals. Status: unknown.
02
Drugs
evofosfamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01522872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522872.